Journal
ANTICANCER RESEARCH
Volume 40, Issue 5, Pages 2409-2418Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.14210
Keywords
Muscle mass loss; sarcopenia; cancer; skeletal muscle index; meta-analysis; review
Categories
Funding
- National Institute of Nursing Research of the US National Institutes of Health [K24NR015340]
Ask authors/readers for more resources
Background/Aim: Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. Materials and Methods: We searched primary original research published through October 2019 in four databases: MEDLINE via PubMed, Scopus, CINAHL, and Embase. Results: Fifteen studies were included, 60% published in the past 2 years (2018-2019). Advanced non-small cell lung cancer was the most frequently reported cancer, and overall survival the most often identified key related factor. Mean difference in skeletal muscle index during chemotherapy was 2.72 (95%CI=1.77-3.67, p=0.00), with muscle loss in males (4.52, 95%CI=3.34-5.71, p=0.00) about 1.6 times higher than that in females (2.86, 95%CI=0.81-4.92, p=0.01). Conclusion: Oncologists should recognize sex- specific differences in skeletal muscle mass loss during chemotherapy and consider adjusting treatment accordingly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available